Pipeline dossier

NIH & clinical-trial pipeline signals for Imunon, Inc. (IMNN)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for IMNN, mapped to public ticker IMNN (CIK 0000749647). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingIMNN35% conf

Imunon, Inc. (IMNN) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Recent SEC 8-K filings

2026-06-30 — 8-K 5.02,9.01 view ↗
2026-06-16 — 8-K 5.02,5.07,9.01 view ↗
2026-06-04 — 8-K 1.01,2.03,3.02,5.03,7.01,9.01 view ↗
2026-05-12 — 8-K 2.02,9.01 view ↗
2026-05-04 — 8-K 5.02,9.01 view ↗

JSON API for this entity →